Перейти к содержимому


  • Публикации

  • Зарегистрирован

  • Посещение


0 Neutral

О candylulu

  • Звание

Посетители профиля

Блок посетителей профиля отключен и не будет отображаться другим пользователям

  1. Are you finding hospital bed products or reliable hospital bed supplier? Do you want to find new business opportunity for your medical products? Ddu(Drugdu.com) helps both buyers and suppliers worldwide to seek new business opportunities through the Drugdu.com Online Platform. We would like to invite the buyers, suppliers, manufacturers and factories to become our members. For more information of hospital bed, you can visit: Drugdu.com Hospital Bed catalog and Supplier, click here Drugdu.com Hospital Bed Online Trade Show, click here About Drugdu.com Drugdu.com (Ddu) is the leading global B2B online platform focused on the cross-border trade of pharmaceuticals and medical devices. As a pioneer in the industry, Ddu’s advanced technology and user-centered services is aimed at not only accelerating the circulation of pharmaceuticals and medical devices around the world, but also simplifying industry trading, making it more practical and efficient. Our expertise in the international medical trade industry has enabled Ddu to provide a full range of solutions for over 100,000 global suppliers and buyers, helping them build and develop channels of communication and expand international business opportunities. Visit www.drugdu.com for more details on how to register as a pharmaceutical and medical device supplier and connect with more buyers to expand your sales marketing. Try to Search #Drugdu.com hospital bed# or #Drugdu.com# on Search Engine( like google) to learn more products and press release. Follow us on Facebook, LinkedIn, Twitter, YouTube and Google Plus or contact Ddu at marketing(at)drugdu(dot)com, or call 86-400-106-9990 From: Get Quality Hospital bed Products or Reliable Suppliers on Drugdu.com
  2. A scientists team from the University of Sheffield have discovered that the human pathogen named Staphylococcus aureus especially MRSA (Methicillin-Resistant Staphylococcus aureus) uses non-threatening bacteria in the skin to initiate infection. Simon Foster, the lead author and Professor of Molecular Microbiology from the University of Sheffield, said "We harbour a vast array of bacteria as microflora in our guts and on our skin so understanding this combination of pathogen, native microflora and host provides new avenues for approaches to prevent and treat infection; A lot of people have been trying to develop a vaccine against the potentially life-threatening virus for a number of years without success; This study has shown how a potentially fatal disease like MRSA gains access to our bodies and how the organisms are able to survive inside immune cells -- phagocytes." Professor Foster further added "All infectious disease starts from an environment of mixed bacteria and other material so this might have much wider ramifications; The study has important implications for the disease because with our work we can drop the infectious dose by over 1,000 fold. Importantly, S. aureus is not a dominant member of our bacterial flora and so this study can explain how relatively few pathogenic bacteria can crowdsource from the other organisms present on our skin to allow it to set an infection that may ultimately prove fatal. It alters the way that we view how infection occurs, the way it should be studied and sets the scene for how it might be tackled." For more information, please visit: https://drugdu.com/ Source from: MRSA Initiates Infection Using Nonthreatening Bacteria in Skin
  3. We look back at a year where advances in pharmaceutical drugs therapies brought new hope to people from across the globe. These steps forward bring with them a sense of suspense as we wait for more ground-breaking work to be accomplished in 2018. Here is Drugdu.com’s list of medical advances that amazed. Radicava for ALSAs the first new treatment to be approved by the FDA in 22 years, Radicava is first on our list of drugs. ALS (amyotrophic lateral sclerosis) also known as Lou Gehrig’s disease, is a neurodegenerative disease that reduces the functionality of muscles in the body. There are still no cures for ALS but during Radicava’s phase 3 trial, 33% of the patients who received the drug reported a slowing down of functional deterioration, meaning a longer term of independence for ALS sufferers. Experimental drug for Huntington’s diseaseThis fatal genetic disorder causes a degradation of nerve cells in the brain, affecting both physical and mental abilities. The new breakthrough is a drug called ASO-HTT-Rx and unlike other pharmaceutical drugs used to manage the symptoms, it must be injected directly into the spinal cord. It may not yet be commercially available but we are waiting with bated breath for more news on this. Ocrevus and clemastine fumarate for MSMS (multiple sclerosis) is an autoimmune disease of the central nervous system where a person’s immune system attacks myelin (the protective substance covering nerve cells). Ocrevus is used to treat primary progressive MS as well as relapsing MS. Patients taking Ocrevus found that is decreased the progression of the disease more so when compared to Rebif, an anti-inflammatory drug used to treat MS. Although this is great news, there is currently no medication for the repair of myelin but, new research has shown that clemastine fumarate, an antihistamine, may be able to reverse and repair the damage caused even if the disease is well advanced. Source from: 3 Amazing Advances in Pharmaceutical Drugs in 2018|Drugdu.com More information, please visit: https://www.drugdu.com/